Big Pharma Ad Budgets Fail to Sway AI Search Results
Pharmaceutical giants pouring billions into direct-to-consumer advertising are discovering that traditional media spending holds little sway over artificial intelligence. A new visibility index reveals that AI engines prioritize companies with high consumer-research footprints, such as Eli Lilly and Novo Nordisk, over those with the largest television ad budgets.
The 2026 Pharma/Rx AI Visibility Index, published by 5W AI Communications, tracks how major drugmakers appear across platforms like ChatGPT, Claude, and Google AI Overviews. While the industry invested roughly $8 billion in U.S. consumer advertising in 2024, the report shows this spend does not correlate with AI citation share. Instead, search engines favor brands like Ozempic, Wegovy, and Mounjaro, which dominate the public discourse through clinical trial records and sustained media coverage.
Eli Lilly leads the sector with a 12.5% citation share, followed closely by Novo Nordisk at 11.5%. In contrast, companies like Merck—which manufactures the world's best-selling drug—rank significantly lower, landing in fifth place. According to 5W founder Ronn Torossian, the discrepancy exists because AI models retrieve durable, peer-reviewed data rather than 30-second television spots. As patients increasingly turn to chat interfaces for medical information before consulting doctors, the pharmaceutical industry’s reliance on legacy broadcast channels is proving to be an inefficient strategy for maintaining digital authority.
Comments (0)
No comments yet. Be the first!